Filament Forms Collaboration With Jaguar Health. Filament and Jaguar Health (JAGX, $0.35, Not Rated) have signed a Letter of Intent to develop botanical compounds for psychiatric uses. We believe Filament's expertise in extraction and manufacturing technologies fits well with Jaguar's extensive research in botanical compounds. Research Collaboration Will Develop Products For Out-licensing. The collaboration intends to develop psychoactive compounds for use in mental health indications, such as attention deficit hyperactivity disorder (ADHD), social anxiety disorder, and related conditions. The companies plan to license commercialization rights to drug candidates developed under the collaboration with an equal profit split. Read More >>